Does Emerald Health Therapeutics Inc Have Any Gas After Today’s Gap Up?

 Does Emerald Health Therapeutics Inc Have Any Gas After Today's Gap Up?

The stock of Emerald Health Therapeutics Inc (CVE:EMH) gapped up by $0.04 today and has $4.14 target or 167.00% above today’s $1.55 share price. The 8 months technical chart setup indicates low risk for the $139.43M company. The gap was reported on Nov, 16 by If the $4.14 price target is reached, the company will be worth $232.85M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 2.15 million shares traded hands or 382.96% up from the average. Emerald Health Therapeutics Inc (CVE:EMH) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.

More news for Emerald Health Therapeutics Inc (CVE:EMH) were recently published by:, which released: “Emerald Health Therapeutics Completes Private Placement and Shares for Debt …” on September 21, 2016.‘s article titled: “Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund” and published on April 28, 2016 is yet another important article.

Emerald Health Therapeutics, Inc., formerly T-Bird Pharma Inc., is a Canada company, which through its subsidiary, Emerald Health Botanicals Inc. , is engaged in the production and sale of medical marihuana. The company has a market cap of $139.43 million. The Company’s segment is production and sales of medical marihuana pursuant to the Marihuana for Medical Purposes Regulations. It currently has negative earnings. Botanicals produces cannabis oils and capsules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Related posts

Leave a Comment